The effect of oral supplementation of Paricalcitol on C-reactive protein levels in chronic kidney disease patients: GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials

CONCLUSION: Oral paricalcitol supplementation in CKD patients can significantly reduce C-reactive protein levels, which may prevent CKD progression.PMID:38395972 | PMC:PMC10885610 | DOI:10.1186/s40360-024-00740-y

Source: BMC Pharmacology and Toxicology - February 23, 2024 Category: Drugs & Pharmacology Authors: Seyyed Mostafa Arabi Mostafa Shahraki-Jazinaki Mahla Chambari Leila Sadat Bahrami Sara Sabeti Mohammaed Ibrahim Mohaildeen Gubari Basil D Roufogalis Amirhossein Sahebkar Source Type: research